Table 2.

Summary of results obtained from the case–control and case–case association analyses of the G84E mutation and prostate cancer risk

Prostate cancer datasetsF_A%F_U%P valueOR (95% CI)
All cases and controls3.50.51.1 × 10−627.1 (5.5–9.3)
UNSa vs. Pcob3.61.01.8 × 10−83.6 (2.2–5.7)
UNS vs. SCRcoc3.60.36.2 × 10−5713.4 (8.9–20.3)
SCRcased vs. SCRco2.20.31.1 × 10−238.0 (4.9–12.9)
SCRcase vs. Pco2.21.00.0046032.1 (1.2–3.6)
All FAMe vs. Pco8.41.02.3 × 10−188.8 (4.9–15.7)
All FAM vs. SCRco8.40.31.8 × 10−8933.1 (19.4–56.5)
All FAM vs. UNS8.43.62.0 × 10−62.5 (1.7–3.6)
All FAM vs. SCRcase8.42.24.2 × 10−114.2 (2.6–6.6)
FAMf vs. Pco7.91.01.5 × 10−138.2 (4.3–16.0)
FAM vs. SCRco7.90.34.4 × 10−6331.1 (16.7–57.8)
FAM vs. UNS7.93.60.00068352.3 (1.4–3.8)
FAM vs. SCRcase7.92.22.6 × 10−73.9 (2.2–6.8)
BPHcaseg vs. BPHcoh2.60.60.0114.6 (1.3–16.2)

NOTE: F_A and F_U represent the frequencies of G84E carriers among affected and unaffected subjects, respectively. All P values are statistically significant.

  • aUNS, unselected cases.

  • bPco, population controls.

  • cSCRco, screening trial controls.

  • dSCRcase, screening trial cases.

  • eAll FAM, familial index cases from all 190 Finnish prostate cancer families.

  • fFAM, familial index cases from the 114 Finnish prostate cancer families analyzed in this study (the 76 familial cases overlapping with the ICPCG dataset are omitted).

  • gBPHcase, patients with BPH with a later diagnosis of prostate cancer.

  • hBPHco, patients with BPH with no diagnosis of prostate cancer.